The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.
作者信息
Ashforth E I, Palmer J L, Bye A, Bedding A
机构信息
Department of Clinical Pharmacokinetics, Glaxo Group Research Ltd, Greenford, Middlesex.
出版信息
Br J Clin Pharmacol. 1994 Apr;37(4):389-91. doi: 10.1111/j.1365-2125.1994.tb04294.x.
Abstract
The pharmacokinetics of the 5-HT3 receptor antagonist ondansetron following an 8 mg i.v. dose were investigated in 12 subjects previously phenotyped with debrisoquine. Six subjects were poor metabolisers (debrisoquine metabolic ratios 29-131) and six were extensive metabolisers (debrisoquine metabolic ratios 0.45-3.4). There was no significant difference in AUC, Cmax, CL or t1/2 between the poor and extensive metabolisers. It is concluded that ondansetron clearance is not mediated exclusively by cytochrome P-450 2D6.
摘要
相似文献
1
The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.
Br J Clin Pharmacol. 1994 Apr;37(4):389-91. doi: 10.1111/j.1365-2125.1994.tb04294.x.
2
Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
Pharmacogenetics. 1991 Oct;1(1):33-41. doi: 10.1097/00008571-199110000-00006.
3
Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.
Br J Clin Pharmacol. 1996 Dec;42(6):707-11. doi: 10.1046/j.1365-2125.1996.00471.x.
4
Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
Pharmacol Toxicol. 1993 Jul;73(1):46-8. doi: 10.1111/j.1600-0773.1993.tb01956.x.
5
Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
Eur J Clin Pharmacol. 1998 Jul;54(5):431-5. doi: 10.1007/s002280050488.
6
Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine.
Br J Clin Pharmacol. 1994 Apr;37(4):383-8. doi: 10.1111/j.1365-2125.1994.tb04293.x.
7
Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
Pain. 1993 Jun;53(3):335-339. doi: 10.1016/0304-3959(93)90229-I.
8
Debrisoquine hydroxylation in a Polish population.
Eur J Clin Pharmacol. 1995;47(6):503-5. doi: 10.1007/BF00193702.
9
Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Clin Pharmacokinet. 2006;45(10):989-1001. doi: 10.2165/00003088-200645100-00003.
10
DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.
Hum Genet. 1993 Oct;92(4):367-72. doi: 10.1007/BF01247337.
引用本文的文献
1
CYP2D6 genotype and associated 5-HT receptor antagonist outcomes: A systematic review and meta-analysis.
Clin Transl Sci. 2025 Feb;18(2):e70108. doi: 10.1111/cts.70108.
2
A Physiologically Based Pharmacokinetic Model to Predict Systemic Ondansetron Concentration in Liver Cirrhosis Patients.
Pharmaceuticals (Basel). 2023 Dec 6;16(12):1693. doi: 10.3390/ph16121693.
3
Associations between ondansetron and the incidence of postoperative nausea and vomiting and food intake in Japanese female undergoing laparoscopic gynecological surgery: a retrospective study.
J Anesth. 2024 Apr;38(2):185-190. doi: 10.1007/s00540-023-03295-0. Epub 2023 Dec 18.
4
Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator.
CPT Pharmacometrics Syst Pharmacol. 2022 Jul;11(7):805-821. doi: 10.1002/psp4.12791. Epub 2022 Apr 18.
5
PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.
Pharmacogenet Genomics. 2019 Jun;29(4):91-97. doi: 10.1097/FPC.0000000000000369.
6
A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.
Clin Pharmacokinet. 2018 Jun;57(6):749-768. doi: 10.1007/s40262-017-0594-5.
7
Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000.
8
Population pharmacokinetics of ondansetron: a covariate analysis.
Br J Clin Pharmacol. 1998 Aug;46(2):117-25. doi: 10.1046/j.1365-2125.1998.00756.x.
9
Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.
Drugs. 1996 Nov;52(5):773-94. doi: 10.2165/00003495-199652050-00010.
10
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.
Clin Pharmacokinet. 1997 Mar;32(3):210-58. doi: 10.2165/00003088-199732030-00004.
本文引用的文献
1
The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.
Br J Clin Pharmacol. 1993 Apr;35(4):441-3. doi: 10.1111/j.1365-2125.1993.tb04164.x.
2
The metabolism of ondansetron.
Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S75-7.
3
Pharmacological and anti-emetic properties of ondansetron.
Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S15-9.
4
Review of methods and criteria for the evaluation of bioequivalence studies.
Eur J Clin Pharmacol. 1990;38(1):5-10. doi: 10.1007/BF00314794.
5
Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers.
Clin Pharmacol Ther. 1992 Jan;51(1):51-5. doi: 10.1038/clpt.1992.7.
6
Tropisetron. A review of the clinical experience.
Drugs. 1992;43 Suppl 3:11-22. doi: 10.2165/00003495-199200433-00005.
7
Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.
J Chromatogr. 1977 Mar 11;133(1):161-6. doi: 10.1016/s0021-9673(00)89216-x.
Zotero 插件